Understanding corticotropin releasing factor neurobiology: Contributions from mutant mice

Neuropeptides

Volumn 33, Issue 1, 1999, Pages 1-12

  Contarino, A ^a   Heinrichs, S C ^a   Gold, L H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; COGNITION; CONTROLLED STUDY; EMOTION; ENERGY BALANCE; GENE DELETION; GENE MUTATION; GENETIC MANIPULATION; HORMONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MOUSE; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 0033082667     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1054/npep.1999.0001     Document Type: Review

References (113)

1. Behan D, Grigoriadis D, Lovenberg T et al. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: Implications for the treatment of CNS disorders. Mol Psychiat 1996; 1: 265-277.
2. Koob G, Heinrichs S, Menzaghi F, Pich E, Britton K. Corticotropin releasing factor, stress and behavior. SINS 1994; 6: 221-229.
3. Pepin M-C, Pothier F, Barden N. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 1992; 355: 725-728.
4. Tronche F, Kellendonk C, Reichardt H, Schutz G. Genetic dissection of glucocorticoid receptor function in mice. Curr Op Gen Dev 1998; 8: 532-538.
5. Gerlai R. Molecular genetic analysis of mammalian behavior and brain processes: Caveats and perspectives. SINS 1996; 8: 153-161.
6. Gold L. Integration of molecular biological techniques and behavioral pharmacology. Behav Pharmacol 1996; 7: 589-615.
7. Grailhe R, Hen R. 5-HT receptor knockouts: Constitutive, inducible or tissue-specific. SINS 1995; 7: 395-400.
8. Mayford M, Abel T, Kandel E. Transgenic approaches to cognition. Curr Opin Neurobiol 1995; 5: 141-148.
9. Wilson M, Tonegawa S. Synaptic plasticity, place cells and spatial memory: Study with second generation knockouts. Trends Neurosci 1997; 20: 102-106.
10. Webster E, Lewis D, Torpy D, Zachman E, Rice K, Chrousos G. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996; 137: 5747-5750.
11. Chen Y, Mansbach R, Winter S et al. Synthesis and oral efficacy of a 4-(Butylethylamino) pyrrolo[2,3-d] pyrimidine: A centrally active corticotropin releasing factor receptor antagonist. J Med Chem 1997; 40: 1749-1754.
12. Baram T, Chalmers D, CHen C, Koutsoukos Y, DeSouza E. The CRF1 receptor mediates the excitatory actions of corticortropin releasing factor (CRF) in the developing rat brain: In vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res 1997; 770: 89-95.
13. Sutton R, Koob G, LeMoal M, Rivier J, Vale W. Corticotropin releasing factor (CRF) produces behavioural activation in rats. Nature 1982; 297: 331-333.
14. BUwalda B, deBoer S, Van Kalkeren A, Koolhaas J. Physiological and behavioral effects of chronic intracerebroventricular infusion of corticotropin-releasing factor in the rat. Psychoneuroendocrinology 1997; 22: 297-309.
15. Cahill L, McGaugh J. Modulation of memory storage. Curr Opin Neurobiol 1996; 6: 237-242.
16. Nemeroff C. New vistas in neuropeptide research in neuropsychiatry: Focus on corticotropin-releasing factor. Neuropsychopharmacology 1992; 6: 69-75.
17. McEwen B, Sapolsky R. Stress and cognitive function. Curr Opin Neurobiol 1995; 5: 205-216.
18. Lupien S, de Leon M, de SAnti S et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nature Neurosci 1998; 1: 69-73.
19. De Souza E, Whitehouse P, Kuhar M, Price D, Vale W. Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature 1986; 13: 593-595.
20. De Souza E, WhitehousePJ, Price D, Vale W. Abnormalities in corticotropin-releasing hormone (CRH) in Alzheimer's disease and other human disorders. Ann NY Acad Sci 1987; 512: 237-247.
21. Pomara N, Singh R, Deptula D et al. CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: Its relationship to severity of dementia and monoamine metabolites. Biol Psychiat 1989; 26: 500-504.
22. Wehner J, Silva A. Importance of strain differences in evaluations of learning and memory processes in null mutants. MRDD Research Reviews 1996; 2: 243-248.
23. Heinrichs S, Stenzel-Poore M, Gold L et al. Learning impairment in transgenic mice with central overexpression of corticotropin-releasing factor. Neuroscience 1996; 74: 303-311.
24. Koob G, Cole B, Swerdlow N, Le Moal M, Britton K. Stress, performance and arousal: Focus on CRF. NIDA Res Monogr 1990; 97: 163-176.
25. Koob G. Arousal, stress and inverted U-shaped curves: Implications for cognitive function. In: Cognitive Neuroscience. Weingartener H, Lister R (eds). Oxford University Press 1991: 300-313.
26. Stenzel-Poore M, Duncan J, Rittenberg M, Bakke A, Heinrichs S. CRH overproduction in transgenic mice: Behavioral and immune system modulation. Ann NY Acad Sci 1996; 780: 36-48.
27. Sapolsky R, Krey L, McEwen B. Prolonged glucocorticoid exposure reduces hippocampal neuron number: Implications for aging. J Neurosci 1985; 5: 1222-1227.
28. Watanabe Y, Gould E, Cameron H, Daniels D, McEwen B. Phenytoin prevents stress and corticosterone induced atrophy of CA3 pyramidal neurons. Hippocampus 1992; 2: 431-435.
29. Bodnoff S, Humphreys A, Lehman J, Diamond D, Rose G, Meaney M. Enduring effects of chronic corticosterone treatment on spatial learning, synaptic plasticity, and hippocampal neuropathology in young and mid-aged rats. J Neurosci 1995; 15: 61-69.
30. Rousse I, Beaulieu S, Rowe W, Meaney M, Barden N, Rochford J. Spatial memory in transgenic mice with impaired glucocorticoid receptor function. NeuroReport 1997; 8: 841-845.
31. Stec I, Barden N, Reul J, Holsboer F. Dexamethasone nonsuppression in transgenic mice expressing antisense RNA to the glucocorticoid receptor. J Psychiatr Res 1994; 28: 1-5.
32. Beaulieu S, Rousse I, Gratton A, Barden N, Rochford J. Behavioral and endocrine impact of impaired type II glucocorticoid receptor function in a transgenic mouse model. Ann NY Acad Sci 1994; 746: 388-391.
33. Montkowski A, Barden N, Wotjak C et al. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol 1995; 7: 841-845.
34. Allain H, Lieury A, Brunet-Bourgin F et al. Antidepressants and cognition: Comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology 1992; 106: S56-61.
35. Rubinow D, Post R, Savard R, Gold P. Cortisol hypersecretion and cognitive impairment in depression. Arch Gen Psychiat 1984; 41: 279-283.
36. Weingartner H, Cohen R, Murphy D, Martello J, Gerdt C. Cognitive processes in depression. Arch Gen Psychiat 1981; 38: 42-47.
37. Contarino A, Dellu F, Koob G et al. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Br Res 1998; in press.
38. COnrad C, Galea L, Kuroda Y, McEwen B. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Behav Neurosci 1996; 110: 1321-1334.
39. Dellu F, Mayo W, Cherkaoui J, Le Moal M, Simon H. A two-trial memory task with automated recording: Study in young and aged rats. Brain Res 1992; 588: 132-139.
40. 1 receptor mRNA expression. J Neurosci 1995; 15:6340-6350.
41. Wu H, Chen K, Lee W, Lee E. Antisense oligonucleotides to corticotropin-releasing factor impair memory retention and increase exploration in rats. Neurosci 1997; 78: 147-153.
42. Heinrichs S, Merlo Pich E, Miczek K, Britton K, Koob G. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res 1992; 581: 190-197.
43. Menzaghi F, Howard R, Heinrichs S, Vale W, Rivier J, Koob G. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J Pharmacol Exp Ther 1994; 269: 564-572.
44. Baldwin H, Rassnick S, Rivier J, Koob G, Britton K. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology 1991; 103: 227-232.
45. Sirinathsinghji D, Rees L, Rivier J, Vale W. Corticotropin-releasing factor is a potent inhibitor of sexual receptivity in the female rat. Nature 1983; 305: 232-235.
46. Ehlers C, Henriksen S, Wang M, Rivier J, Vale W, Bloom F. Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Res 1983; 278: 332-336.
47. Nemeroff C, Widerlov E, Bissette G et al. Elevated concentrations of CSF corticotropin releasing factor-like immunoreactivity in depressed patients. Science 1984; 226: 1342-1344.
48. Holsboer F, Von Bardeleben U, Gerken A, Stalla G, Muller O. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. New Engl J Med 1984; 311: 1127.
49. Banki C, Karmacsi L, Bissette G, Nemeroff C. CSF corticotropin-releasing hormone and somatostatin in major depression: Response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 1992; 2: 107-113.
50. Nemeroff C, Bissette G, Akil H, Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotropin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 1991; 158: 59-63.
51. Smith G, Aubry J-M, Dellu F et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998; 20: 1093-1102.
52. Schulz D, Mansbach R, Sprouse J et al. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci 1996; 93: 10477-10482.
53. Bornstein S, Webster E, Tropy D et al. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonists on pituitary adrenal function, body weight, and metabolic regulation. Endocrinology 1998; 139: 1546-1555.
54. Timpl P, Spanagel R, Sillaber I et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin releasing hormone receptor 1. Nature Genetics 1998; 19: 162-166.
55. Skutella T, Criswell H, Moy S et al. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide induces anxiolytic effects in rat. NeuroReport 1994; 5: 2181-2185.
56. Skutella T, Probst J, Renner U, Holsboer F, Behl C. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience 1998; 85: 795-805.
57. 1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regulatory Peptides 1995; 59: 229-239.
58. 2, receptors mediated anxiogenic-like behavior. Regulatory Peptides 1997; 71: 15-21.
59. Lundkvist J, Chai Z, Teheranian R et al. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 1996; 309: 195-200.
60. GRiebel G, Perrault G, Sanger D. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents-comparison with diazepam and buspirone. Psychopharmacology 1998; 138: 55-66.
61. 1 receptor antagonist. Eur J Pharmacol 1997; 323: 21-26.
62. Maier S, Seligman M. Learned helplessness: Theory and evidence. J Exp Psychol 1976; 1: 3-46.
63. Heinrichs S, Min H, Tamraz S, Carmouché M, Boehme S, Vale W. Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 1997; 22: 215-224.
64. Thase M, Reynolds C, Jennings J et al. Nocturnal penile tumescence is diminished in depressed men. Biol Psychiat 1988; 24: 33-46.
65. Stenzel-Poore M, Heinrichs S, Rivest S, Koob G, Vale W. Overproduction of corticotropin releasing factor in transgenic mice: A genetic model of anxiogenic behavior. J Neurosci 1994; 14: 2579-2584.
66. Berridge C, Dunn A. CRF and restraint-stress decrease exploratory behavior in hypophysectomized mice. Pharmacol Biochem Behav 1989; 34: 517-519.
67. Britton K, Lee G, Dana R, Risch S, Koob G. Activating and 'anxiogenic' effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone. Life Sci 1986; 39: 1281-1286.
68. Orth D, Mount C. Specific high-affinity binding protein for human corticotropin-releasing hormone in normal human plasma. Biochem Biophys Res Comm 1987; 143: 411-417.
69. Potter E, Behan D, Fischer W, Linton E, Lowry P, Vale W. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins. Nature 1991; 349: 423-426.
70. Cortright D, Nicoletti A, Seasholtz A. Molecular and biochemical characterization of the mouse brain corticotropin-releasing hormone-binding protein. Mol Cell Endocrinol 1995; 111: 147-157.
71. Behan D, Potter E, SUtton S, Fischer W, Lowry P, Vale W. Corticotropin-releasing factor-binding protein. A putative peripheral and central modulator of the CRF family of neuropeptides. Ann NY Acad Sci 1993; 697: 1-8.
72. Linton E, Perkins A, Woods R et al. Corticotropin releasing hormone-binding protein (CRH-BP): Plasma levels decrease during the third trimester of normal human pregnancy. J Clin Endocrinol Metab 1993; 76: 260-262.
73. Burrows H, Nakajima M, Lesh J et al. Excess corticotropin releasing hormone-binding protein in the hypothalamic pituitary adrenal axis in transgenic mice. J Clin Invest 1998; 101: 1439-1447.
74. Lovejoy D, Aubry J-M, Turnbull A et al. Ectopic expression of the CRF-binding protein: Minor impact on HPA axis regulation but induction of sexually dimorphic weight gain. J Neuroendocrinol 1998; 10: 483-491.
75. Ramesh T, Karolyi I, Nakajima M, Camper S, Seasholtz A. Increased anxiety in corticotropin releasing hormone-binding protein-deficient mice. Brain Res 1998; 809: A23.
76. Jensen L, Stephens D, Sarter M, Petersen E. Bidirectional effects of beta-carbolines and benzodiazepines on cognitive processes. Brain Res Bull 1987; 19: 359-364.
77. Rochford J, Beaulieu S, Rousse I, Glowa J, Barden N. Behavioral reactivity to aversive stimuli in a transgenic mouse model of impaired glucocorticoid (type II) receptor function: Effects of diazepam and FG-7142. Psychopharmacology 1997; 132: 145-152.
78. Sapolsky R, Rivier C, Yamamoto G, PLotsky P, Vale W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987; 238: 522-524.
79. Munck A, Guyre P, Holbrook N. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocrin Rev 1984; 5: 25-44.
80. Webster E, Torpy D, Elenkov I, Chrousos G. Corticotropin-releasing hormone and inflammation. Ann NY Acad Sci 1998; 840: 21-32.
81. Boehme S, Gaur A, Crowe P et al. Immunosuppressive phenotype of corticotropin-releasing factor transgenic mice is reversed by adrenalectomy. Cellular Immunol 1997; 176: 103-112.
82. Laflamme N, Barden N, Rivest S. Corticotropin-releasing factor and glucocorticoid receptor (GR) gene expression in the paraventricular nucleus of immune-challenged transgenic mice expressing type II GR antisense ribonucleic acid. J Mol Neurosci 1997; 8: 165-179.
83. Rivest S, Laflamme N, Nappi R. Immune challenge and immobilization stress induced transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. J Neurosci 1995; 15: 2680-2695.
84. Diagnostic and Statistical Manual of Mental Disorders: DSM IV (Fourth Edition), American Psychiatric Association, Washington, DC, 1994.
85. Carroll M, France C, Meisch R. Food deprivation increases oral and intravenous drug intake in rats. Science 1979; 205: 319-321.
86. Tidey J, Miczek K. Acquisition of cocaine self-administration after social stress: Role of accumbens dopamine. Psychopharmacology 1997; 130: 203-212.
87. Goeders N, Guerin G. Non-contingent electric footshock facilitates the acquisition of intravenous cocaine self-administration in rats. Psychopharmacology 1994; 114:63-70.
88. Shaham Y, Alvares K, Nespor S, Grunberg N. Effect of stress on oral morphine and fentanyl self-administration in rats. Pharmacol Biochem Behav 1992; 41: 615-619.
89. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 1981; 213: 1394-1397.
90. Rodriguez de Fonseca F, Carrera M, Navarro M, Koob G, Weiss F. Activation of corticotropin releasing factor in the limbic system during cannabinoid withdrawal. Science 1997; 276: 2050-2054.
91. Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob G. Increase of extracellular corticotropin releasing factor like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995; 15: 5439-5447.
92. Adinoff B, Anton R, Linnoila M, Guidotti A, Nemeroff C, Bissette G. Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. Neuropsychopharmacology 1996; 15: 288-295.
93. Heinrichs S, Menzaghi F, Schulteis G, Koob G, Stinus L. Suppression of corticotropin releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 1995; 6: 74-80.
94. Rassnick S, Heinrichs S, Britton K, Koob G. Microinjection of a corticotropin releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic like effects of ethanol withdrawal. Brain Res 1993; 605: 25-32.
95. Heinrichs S, Klaassen A, Koob G, Schulteis G, Ahmed S, De Souza E. Corticotropin-releasing factor receptor blockade enhances conditioned aversive properties of cocaine in rats. Psychopharmacology 1998; 136: 247-255.
96. Zhou Y, Spangler R, LaForge S, Maggos C, Ho A, Kreek M. Corticotropin-releasing factor and type 1 corticotropin releasing factor receptor messenger RNAs in rat brain and pituitary during "binge" pattern cocaine administration and chronic withdrawal. J Pharmacol Exp Ther 1996; 279: 351-358.
97. Sarnyai Z, Biro E, Gardi J, Vecsernyes M, JUlesz J, Telegdy G. Brain corticotropin releasing factor mediates 'anxiety like' behavior induced by cocaine withdrawal in rats. Brain Research 1995; 675: 89-97.
98. Heinrichs S, Lapansky J, Behan D et al. Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. Proc Natl Acad Sci 1996; 93: 15475-15480.
99. Iredale P, Alvaro J, Lee Y, Terwilliger R, Chen Y, Duman R. CRF-R1 Expression is Regulated by Opiate Withdrawal and Contributes to Withdrawal Behavior. Submitted.
100. 1 receptor attenuates stress induced relapse to drug seeking in cocaine and heroin trained rats. Psychopharmacology 1998; 137: 184-190.
101. Simar M, Saphier D, Goeders N. Differential neuroendocrine and behavioral responses to cocaine in Lewis and Fischer rats. Neuroendocrinology 1996; 63: 93-100.
102. 9-41. Pharmacol Biochem Behav 1994; 48: 497-503.
103. Deroche V, Caine S, Heyser C, Polis I, Koob G, Gold L. Differences in the liability to self-administer intravenous cocaine between C57BL/6 x SJL and BALB/cByJ mice. Pharmacol Biochem Behav 1997; 57: 429-440.
104. Richard D. Involvement of corticotropin releasing factor in the control of food intake and energy expenditure. Ann NY Acad Sci 1993; 697: 155-172.
105. Gudmundsson K, Majzoub J. CRH deficiency attenuates weight loss independent of effects on food intake. Endocrine Society Abstracts 1998; 95:.
106. Weininger S, Muglia L, Berridge C et al. Behavioral characterization of corticotropin releasing hormone deficient mice. Soc Neurosci Abstr 1997; 23: 314.
107. Rohner-Jeanrenaud F, Walker C-D, Greco-Perotto R, Jeanrenaud B. Central corticotropin releasing factor administration prevents the excessive body weight gain of genetically obese (fa/fa) rats. Endocrinol 1989; 124: 733-739.
108. Vaughan J, Donaldson C, Bittencourt J et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995; 378: 287-292.
109. Spina M, Merlo-Pich E, Chan R et al. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996; 273: 1561-1564.
110. Behan D, Khongsaly O, Ling N, De Souza E. Urocortin interaction with corticotropin-releasing factor (CRF) binding protein (CRF-BP): A novel mechanism for elevating "free" CRF levels in human brain. Brain Research 1996; 725: 263-267.
111. Timofeeva E, Richard D. Functional activation of CRH neurons and expression of the genes encoding CRH and its receptors in food-deprived lean (Fa/?) and obese (fa/fa) Zucker rats. Neuroendocrinol 1997; 66: 327-340.
112. Chua Jr. S, Chung W, Wu-Peng X et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996; 271: 994-996.
113. Muglia L, Jacobson L, Dikkes P, Majzoub J. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glutcocorticoid need. Nature 1995; 373: 427-432.